A5026634089- Parkinson's Disease Mechanisms and Treatments
- Epigenetics and DNA Methylation
- RNA regulation and disease
- Alzheimer's disease research and treatments
- Nuclear Receptors and Signaling
- Nerve injury and regeneration
- Neurological disorders and treatments
- Autophagy in Disease and Therapy
- Botulinum Toxin and Related Neurological Disorders
- Neurological diseases and metabolism
- Neuroinflammation and Neurodegeneration Mechanisms
- Neuroscience and Neuropharmacology Research
- Histone Deacetylase Inhibitors Research
- Sleep and Wakefulness Research
- RNA modifications and cancer
- Extracellular vesicles in disease
- MicroRNA in disease regulation
- Metal-Organic Frameworks: Synthesis and Applications
- Peroxisome Proliferator-Activated Receptors
- Autism Spectrum Disorder Research
- Restless Legs Syndrome Research
- Cellular transport and secretion
University of Göttingen
2019-2023
Universitätsmedizin Göttingen
2018-2023
Weatherford College
2023
Nanoscale Microscopy and Molecular Physiology of the Brain Cluster of Excellence 171 — DFG Research Center 103
2018-2021
Biomedical Research Foundation of the Academy of Athens
2016-2020
Abstract Parkinson’s disease is increasingly prevalent. It progresses from the pre-motor stage (characterised by non-motor symptoms like REM sleep behaviour disorder), to disabling motor stage. We need objective biomarkers for early/pre-motor stages be able intervene and slow underlying neurodegenerative process. Here, we validate a targeted multiplexed mass spectrometry assay blood samples recently diagnosed patients ( n = 99), individuals with isolated disorder (two cohorts: 18 54...
Abstract Lysosomal and synaptic dysfunctions are hallmarks in neurodegeneration potentially relevant as biomarkers, but data on early Parkinson’s disease (PD) is lacking. We performed targeted mass spectrometry with an established protein panel, assessing autophagy function cerebrospinal fluid (CSF) of drug-naïve de novo PD, sex-/age-matched healthy controls (HC) cross-sectionally (88 46 HC) longitudinally (104 58 over 10 years. Multiple markers autophagy, plasticity, secretory pathways were...
α-Synuclein is readily released in human and mouse brain parenchyma, even though the normal function of secreted protein has not been yet elucidated. Under pathological conditions, such as Parkinson's disease, pathologically relevant species α-synuclein have shown to propagate between neurons a prion-like manner, although mechanism by which transfer induces degeneration remains be identified. Due this evidence extracellular now considered critical target hinder disease progression disease....
Background: Synucleinopathies are disorders characterized by the abnormal accumulation of α-synuclein (aSyn). Synaptic compromise is observed in synucleinopathies parallel to aSyn aggregation and accompanied transcript deregulation. Objective: We sought identify microRNAs associated with synaptic processes that may contribute dysfunction degeneration synucleinopathies. Methods: performed small RNA-sequencing midbrain from 6-month-old transgenic mice expressing A30P mutant aSyn, followed...
Abstract Parkinson’s disease (PD) is a neurological disorder with complex interindividual etiology that becoming increasingly prevalent worldwide. Elevated alpha-synuclein levels can increase risk of PD and may influence epigenetic regulation pathways. Here, we report genome-wide DNA methylation hydroxymethylation alterations associated overexpression two PD-linked variants (wild-type A30P) in LUHMES cells differentiated to dopaminergic neurons. Alpha-synuclein altered at thousands CpGs...
Parkinson's disease is biochemically characterized by the deposition of aberrant aggregated α-synuclein in affected neurons. The aggregation properties greatly depend on its affinity to bind cellular membranes via a dynamic interaction with specific lipid moieties. In particular, can interact arachidonic acid (AA), polyunsaturated fatty acid, manner that promotes formation α-helix enriched assemblies. context, AA released from membrane phospholipids phospholipase A2 (PLA2 ). To investigate...
N6-methyladenosine (m6A) is the most abundant and conserved transcriptional modification in eukaryotic RNA, regulating RNA fate. While functions of m6A development mammalian brain have been extensively studied, its roles synaptic plasticity, cognitive decline, motor function, or other circuits remain underexplored. To date, role this Parkinson's disease (PD) synucleinopathies has largely unknown. Here, we investigated epitranscriptome a mouse model synucleinopathy. We performed...
Abstract Background Mutations and multiplications in the gene encoding for alpha-synuclein are associated with Parkinson’s disease (PD). However, not all individuals variants develop PD, suggesting that additional factors involved. We hypothesized increased might alter epigenetic regulation of PD pathways. Objectives To identify genome-wide DNA methylation hydroxymethylation changes induced by overexpression two human dopaminergic neurons, to relate these corresponding transcriptome. Methods...
<title>Abstract</title> Parkinson’s disease (PD) is an increasingly prevalent neurodegenerative for which readily available and non-invasive diagnostic biomarkers are scarce. Here, we present a panel of proteomic plasma biomarkers, capable discriminating between PD healthy controls with 100% accuracy in machine learning model. We performed discovery proteomics study on newly diagnosed patients controls, followed by multiplexed targeted assay applied to 99 de novo 36 controls. The model...
<title>Abstract</title> Lysosomal and synaptic dysfunctions are hallmarks in multiple neurodegenerative diseases including Alzheimer’s disease Parkinson’s (PD) could be relevant from a biomarker perspective. Biomarker data on prodromal early PD not yet available. We performed targeted mass spectrometry measurements cross-sectionally longitudinally over 10 years with an established panel, assessing autophagy function cerebrospinal fluid (CSF) subjects isolated REM sleep behavior disorder...